RecruitingPhase 4NCT05345613

Tranexamic Acid During Colonic Endoscopic Resection Procedures

Usage of Tranexamic Acid During Colonic Endoscopic Resection Procedures for Reduction Intraprocedural and Postprocedural Bleeding

Sponsor

Assaf-Harofeh Medical Center

Enrollment

200 participants

Start Date

May 1, 2022

Study Type

INTERVENTIONAL

Conditions

Colon Neoplasm

Summary

Colonoscopy with polypectomy reduces the incidence and mortality associated with colon cancer. However, polypectomy is associated with adverse events such as bleeding. Tranexamic acid (TXA) is a synthetic derivative of lysine that exerts antifibrinolytic effects and may prevent bleeding. The investigators aim to evaluate the effect of local TXA on preventing intraprocedural and postprocedural bleeding in patients undergoing endoscopic mucosal resection (EMR) of large colon polyps.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing whether tranexamic acid — a medication that reduces bleeding by preventing blood clot breakdown — can reduce bleeding complications during colon polyp removal procedures (endoscopic resection) performed via colonoscopy. **You may be eligible if...** - You are over 18 years old - You are referred to a tertiary academic center for endoscopic removal of colon lesions (neoplastic or non-neoplastic polyps) **You may NOT be eligible if...** - You have had allergic reactions to tranexamic acid - You have a history of seizures - You are pregnant Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.